cilostazol has been researched along with Aneurysm, Anterior Cerebral Artery in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 9.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "Previous studies with small sample size have shown that cilostazol can reduce the risk of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 8.90 | Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Guo, ZN; Niu, PP; Xing, YQ; Yang, G; Yang, Y, 2014) |
| "This study aimed to reveal the clinical significance of the platelet reactivity unit (PRU) and the efficacy of adjunctive cilostazol and its association with thromboembolic and microembolic events after coil embolization for unruptured intracranial aneurysms (UIAs)." | 8.12 | Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: Clinical significance of platelet reactivity unit and adjunctive cilostazol. ( Ahn, JS; Heo, Y; Kim, GJ; Lee, DH; Moon, EJ; Park, JC; Park, W, 2022) |
| " Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel." | 7.83 | Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 5.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "Previous studies with small sample size have shown that cilostazol can reduce the risk of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 4.90 | Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Guo, ZN; Niu, PP; Xing, YQ; Yang, G; Yang, Y, 2014) |
| "This study aimed to reveal the clinical significance of the platelet reactivity unit (PRU) and the efficacy of adjunctive cilostazol and its association with thromboembolic and microembolic events after coil embolization for unruptured intracranial aneurysms (UIAs)." | 4.12 | Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: Clinical significance of platelet reactivity unit and adjunctive cilostazol. ( Ahn, JS; Heo, Y; Kim, GJ; Lee, DH; Moon, EJ; Park, JC; Park, W, 2022) |
| "Aspirin prevented aneurysm rupture in a mouse intracranial aneurysm model, while cilostazol did not." | 3.88 | Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model. ( Hiramatsu, H; Hokamura, K; Kamio, Y; Kimura, T; Makino, H; Namba, H; Suzuki, T; Umemura, K; Yamasaki, T, 2018) |
| " Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel." | 3.83 | Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016) |
| "If both treatments are available for ruptured aneurysms, clinicians should choose EC on the basis of its ability to prevent DIND." | 1.72 | Comparison of Symptomatic Vasospasm after Surgical Clipping and Endovascular Coiling. ( Adachi, H; Akiyama, T; Asakura, K; Fukuda, T; Fukui, N; Fukumitsu, R; Horii, R; Imamura, H; Kajiura, S; Omura, Y; Sakai, N; Sasaki, N; Shigeyasu, M; Sunohara, T; Tani, S, 2022) |
| "To clarify the frequency of Japanese patients who are resistant to antiplatelet agents, and then clarify correlations between resistance and thromboembolic adverse events in neurointervention." | 1.38 | [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention]. ( Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Naito, T; Wakabayashi, T; Yamanouchi, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, GJ | 1 |
| Heo, Y | 1 |
| Moon, EJ | 1 |
| Park, W | 1 |
| Ahn, JS | 1 |
| Lee, DH | 1 |
| Park, JC | 1 |
| Imamura, H | 1 |
| Tani, S | 1 |
| Adachi, H | 1 |
| Fukumitsu, R | 1 |
| Sunohara, T | 1 |
| Fukui, N | 1 |
| Omura, Y | 1 |
| Sasaki, N | 1 |
| Akiyama, T | 1 |
| Fukuda, T | 1 |
| Kajiura, S | 1 |
| Shigeyasu, M | 1 |
| Asakura, K | 1 |
| Horii, R | 1 |
| Sakai, N | 1 |
| Yu, W | 1 |
| Huang, Y | 1 |
| Zhang, X | 1 |
| Luo, H | 1 |
| Chen, W | 1 |
| Jiang, Y | 1 |
| Cheng, Y | 1 |
| Suzuki, T | 1 |
| Kamio, Y | 1 |
| Makino, H | 1 |
| Hokamura, K | 1 |
| Kimura, T | 1 |
| Yamasaki, T | 1 |
| Hiramatsu, H | 1 |
| Umemura, K | 1 |
| Namba, H | 1 |
| Sugimoto, K | 1 |
| Nomura, S | 1 |
| Shirao, S | 1 |
| Inoue, T | 1 |
| Ishihara, H | 1 |
| Kawano, R | 1 |
| Kawano, A | 1 |
| Oka, F | 1 |
| Suehiro, E | 1 |
| Sadahiro, H | 1 |
| Shinoyama, M | 1 |
| Oku, T | 1 |
| Maruta, Y | 1 |
| Hirayama, Y | 1 |
| Hiyoshi, K | 1 |
| Kiyohira, M | 1 |
| Yoneda, H | 1 |
| Okazaki, K | 1 |
| Dreier, JP | 1 |
| Suzuki, M | 1 |
| Shan, T | 1 |
| Zhang, T | 1 |
| Qian, W | 1 |
| Ma, L | 1 |
| Li, H | 1 |
| You, C | 1 |
| Xie, X | 1 |
| Kono, K | 1 |
| Shintani, A | 1 |
| Yoshimura, R | 1 |
| Okada, H | 1 |
| Tanaka, Y | 1 |
| Fujimoto, T | 1 |
| Tomura, N | 1 |
| Terada, T | 1 |
| Niu, PP | 1 |
| Yang, G | 1 |
| Xing, YQ | 1 |
| Guo, ZN | 1 |
| Yang, Y | 1 |
| Nakagawa, I | 1 |
| Park, HS | 1 |
| Yokoyama, S | 1 |
| Wada, T | 1 |
| Hironaka, Y | 1 |
| Motoyama, Y | 1 |
| Takayama, K | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Haraguchi, K | 1 |
| Miyachi, S | 1 |
| Izumi, T | 1 |
| Matsubara, N | 1 |
| Naito, T | 1 |
| Asai, T | 1 |
| Yamanouchi, T | 1 |
| Wakabayashi, T | 1 |
| Yi, HJ | 1 |
| Cheong, MA | 1 |
| Kim, DW | 1 |
3 reviews available for cilostazol and Aneurysm, Anterior Cerebral Artery
| Article | Year |
|---|---|
Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta‑analysis and systematic review.
Topics: Cardiovascular Agents; Cilostazol; Humans; Intracranial Aneurysm; Network Meta-Analysis; Neuroprotec | 2021 |
Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Topics: Brain Ischemia; Cardiovascular Agents; Cerebral Infarction; Cilostazol; Humans; Intracranial Aneurys | 2020 |
Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Topics: Cilostazol; Humans; Intracranial Aneurysm; Neuroprotective Agents; Randomized Controlled Trials as T | 2014 |
1 trial available for cilostazol and Aneurysm, Anterior Cerebral Artery
| Article | Year |
|---|---|
Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Cortical Spreading Depressio | 2018 |
7 other studies available for cilostazol and Aneurysm, Anterior Cerebral Artery
| Article | Year |
|---|---|
Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: Clinical significance of platelet reactivity unit and adjunctive cilostazol.
Topics: Cilostazol; Clopidogrel; Embolization, Therapeutic; Endovascular Procedures; Humans; Intracranial An | 2022 |
Comparison of Symptomatic Vasospasm after Surgical Clipping and Endovascular Coiling.
Topics: Aneurysm, Ruptured; Cilostazol; Humans; Intracranial Aneurysm; Retrospective Studies; Subarachnoid H | 2022 |
Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model.
Topics: Aneurysm, Ruptured; Animals; Aspirin; Cerebral Arteries; Cilostazol; Cyclooxygenase 2; Cyclooxygenas | 2018 |
Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2013 |
Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Dia | 2016 |
[Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention].
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Resistance; Female; Humans; Intracranial Aneurys | 2012 |
Reversible shortness of breath caused by the antiplatelet agent, clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dyspnea; Embolization, Therapeutic; Endovascular Procedures; Human | 2013 |